Erratum to: N-cadherin Restrains PTH Activation of Lrp6/β-catenin Signaling and Osteoanabolic Action: N-CADHERIN AND PTH SIGNALING (Journal of Bone and Mineral Research, (2015), 30, 2, (274-285), 10.1002/jbmr.2323);N-cadherin restrains PTH activation of Lrp6/β-catenin signaling and osteoanabolic action

Journal of Bone and Mineral Research

Volumn 30, Issue 2, 2015, Pages 274-285

  Revollo, Leila ^a   Kading, Jacqueline ^a   Jeong, Sung Yeop ^a   Li, Jiemin ^a   Salazar, Valerie ^a,b   Mbalaviele, Gabriel ^a   Civitelli, Roberto ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

B catenin; Cadherins; Lrp6; Parathyriod hormone; PKA

Indexed keywords

BETA CATENIN; CARBOXY TERMINAL TELOPEPTIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; LYMPHOID ENHANCER FACTOR 1; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN RECEPTOR; PARATHYROID HORMONE[1-34]; PROTEIN; PROTEIN AXIN2; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG; ANABOLIC AGENT; CADHERIN; OSTERIX PROTEIN, MOUSE; PARATHYROID HORMONE RECEPTOR 1; PROTEIN BINDING; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOSYNTHESIS; BONE MARROW STROMA CELL; BONE MASS; CARBOXY TERMINAL SEQUENCE; CELL LINEAGE; CONTROLLED STUDY; GENE EXPRESSION; GENOTYPE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRABECULAR BONE; TRANSCRIPTION INITIATION; WNT SIGNALING PATHWAY; ANIMAL; BIOLOGICAL MODEL; BONE; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; KNOCKOUT MOUSE; METABOLISM; PHOSPHORYLATION;

ANABOLIC AGENTS; ANIMALS; BETA CATENIN; BONE AND BONES; CADHERINS; GENE EXPRESSION REGULATION; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-6; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, BIOLOGICAL; OSTEOBLASTS; PARATHYROID HORMONE; PHOSPHORYLATION; PROTEIN BINDING; RECEPTOR, PARATHYROID HORMONE, TYPE 1; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; TRANSCRIPTION FACTORS;

EID: 84921786328     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.3845     Document Type: Erratum

References (54)

1. Aslan D, Andersen MD, Gede LB, et al. Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans. Scand J Clin Lab Invest. 2012;72(1):14-22.
2. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev. 1993;14:690-709.
3. Datta NS, Abou-Samra AB. PTH and PTHrP signaling in osteoblasts. Cell Signal. 2009;21(8):1245-54.
4. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19(2):179-92.
5. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet. 2004;5(9):691-701.
6. Monroe DG, McGee-Lawrence ME, Oursler MJ, Westendorf JJ. Update on Wnt signaling in bone cell biology and bone disease. Gene. 2012;492(1):1-18.
7. Joeng KS, Schumacher CA, Zylstra-Diegel CR, Long F, Williams BO. Lrp5 and Lrp6 redundantly control skeletal development in the mouse embryo. Dev Biol. 2011;359(2):222-9.
8. Riddle RC, Diegel CR, Leslie JM, et al. Lrp5 and Lrp6 exert overlapping functions in osteoblasts during postnatal bone acquisition. PLoS One. 2013;8(5):e63323.
9. Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/b-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell. 2005;8(5):739-50.
10. Rodda SJ, McMahon AP. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development. 2006;133(16):3231-44.
11. Guo J, Liu M, Yang D, et al. Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab. 2010;11(2):161-71.
12. Li C, Xing Q, Yu B, et al. Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH. J Bone Miner Res. 2013;28(10):2094-108.
13. Wan M, Yang C, Li J, et al. Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev. 2008;22(21):2968-79.
14. Wan M, Li J, Herbst K, et al. LRP6 mediates cAMP generation by G protein-coupled receptors through regulating the membrane targeting of Galpha(s). Sci Signal. 2011;4(164):ra15.
15. Heuberger J, Birchmeier W. Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling. Cold Spring Harb Perspect Biol. 2010;2(2):a002915.
16. Fagotto F. Looking beyond the Wnt pathway for the deep nature of beta-catenin. EMBO Rep. 2013;14(5):422-33.
17. Di Benedetto A, Watkins M, Grimston S, et al. N-cadherin and cadherin 11 modulate postnatal bone growth and osteoblast differentiation by distinct mechanisms. J Cell Sci. 2010;123(Pt 15):2640-8.
18. Hay E, Laplantine E, Geoffroy V, et al. N-cadherin interacts with axin and LRP5 to negatively regulate Wnt/beta-catenin signaling, osteoblast function, and bone formation. Mol Cell Biol. 2009;29(4):953-64.
19. Wheelock MJ, Johnson KR. Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol. 2003;19:207-35.
20. Derycke LD, Bracke ME. N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int J Dev Biol. 2004;48(5-6):463-76.
21. Nelson WJ, Nusse R. Convergence of Wnt, b-catenin, and cadherin pathways. Science. 2004;303(5663):1483-7.
22. Marie PJ, Hay E, Modrowski D, Revollo L, Mbalaviele G, Civitelli R. Cadherin-mediated cell-cell adhesion and signaling in the skeleton. Calcif Tissue Int. 2014;94(1):46-54.
23. Hay E, Nouraud A, Marie PJ. N-cadherin negatively regulates osteoblast proliferation and survival by antagonizing Wnt, ERK and PI3K/Akt signalling. PLoS One. 2009;4(12):e8284.
24. Hay E, Buczkowski T, Marty C, Da Nascimento S, Sonnet P, Marie PJ. Peptide-based mediated disruption of N-cadherin-LRP5/6 interaction promotes Wnt signaling and bone formation. J Bone Miner Res. 2012;27(9):1852-63.
25. Ke J, Zhang C,Harikumar KG, et al. Modulation of beta-catenin signaling by glucagon receptor activation. PLoS One. 2012;7(3):e33676.
26. Greenbaum AM, Revollo LD, Woloszynek JR, Civitelli R, Link DC. N-cadherin in osteolineage cells is not required for maintenance of hematopoietic stem cells. Blood. 2012;120(2):295-302.
27. Kostetskii I, Li J, Xiong Y, et al. Induced deletion of the N-cadherin gene in the heart leads to dissolution of the intercalated disc structure. Circ Res. 2005;96(3):346-54.
28. Truett GE, Heeger P, Mynatt RL, Truett AA, Walker JA, Warman ML. Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). Biotechniques. 2000;29(1): 52, 54.
29. Watkins MP, Norris JY, Grimston SK, et al. Bisphosphonates improve trabecular bone mass and normalize cortical thickness in ovariectomized, osteoblast connexin43 deficient mice. Bone. 2012;51(4):787-94.
30. Watkins M, Grimston SK, Norris JY, et al. Osteoblast connexin43 modulates skeletal architecture by regulating both arms of bone remodeling. Mol Biol Cell. 2011;22(8):1240-51.
31. Taurin S, Sandbo N, Qin Y, Browning D, Dulin NO. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem. 2006;281(15):9971-6.
32. Chijiwa T, Mishima A, Hagiwara M, et al. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem. 1990;265(9):5267-72.
33. Koe RC, Clohisy JC, Tyson DR, Pulumati MR, Cook TF, Partridge NC. Parathyroid hormone versus phorbol ester stimulation of activator protein-1 gene family members in rat osteosarcoma cells. Calcif Tissue Int. 1997;61(1):52-8.
34. Fu Q, Manolagas SC, O'Brien CA. Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol. 2006;26(17):6453-68.
35. Filali M, Cheng N, Abbott D, Leontiev V, Engelhardt JF. Wnt-3A/beta-catenin signaling induces transcription from the LEF-1 promoter. J Biol Chem. 2002;277(36):33398-410.
36. Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol. 2002;22(4):1172-83.
37. O'Brien CA, Plotkin LI, Galli C, et al. Control of bonemass and remodeling by PTH receptor signaling in osteocytes. PLoS One. 2008;3(8):e2942.
38. Robling AG, Kedlaya R, Ellis SN, et al. Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice. Endocrinology. 2011;152(8):2963-75.
39. Bedi B, Li JY, Tawfeek H, et al. Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH. Proc Natl Acad Sci USA. 2012;109(12):E725-33.
40. Davey RA, Clarke MV, Sastra S, et al. Decreased body weight in young Osterix-Cre transgenic mice results in delayed cortical bone expansion and accrual. Transgenic Res. 2012;21(4):885-93.
41. Vinyoles M, Del Valle-Perez B, Curto J, et al. Multivesicular GSK3 sequestration upon Wnt signaling is controlled by p120-catenin/cadherin interaction with LRP5/6. Mol Cell. 2014;53(3):444-57.
42. Cupp ME, Nayak SK, Adem AS, Thomsen WJ. Parathyroid hormone (PTH) and PTH-related peptide domains contributing to activation of different PTH receptor-mediated signaling pathways. J Pharmacol Exp Ther. 2013;345(3):404-18.
43. Bisello A, Chorev M, Rosenblatt M, Monticelli L, Mierke DF, Ferrari SL. Selective ligand-induced stabilization of active and desensitized parathyroid hormone type 1 receptor conformations. J Biol Chem. 2002;277(41):38524-30.
44. Gumbiner BM. Signal transduction of beta-catenin. Curr Opin Cell Biol. 1995;7(5):634-40.
45. Gumbiner BM. Regulation of cadherin adhesive activity. J Cell Biol. 2000;148(3):399-404.
46. Powell WF Jr, Barry KJ, Tulum I, et al. Targeted ablation of the PTH/PTHrP receptor in osteocytes impairs bone structure and homeostatic calcemic responses. J Endocrinol. 2011;209(1):21-32.
47. Novince CM, Koh AJ, Michalski MN, et al. Proteoglycan 4, a novel immunomodulatory factor, regulates parathyroid hormone actions on hematopoietic cells. Am J Pathol. 2011;179(5):2431-42.
48. Saini V, Marengi DA, Barry KJ, et al. Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH. J Biol Chem. 2013;288(28):20122-34.
49. Maes C, Kobayashi T, Selig MK, et al. Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels. Dev Cell. 2010;19(2):329-44.
50. Szulc P, Seeman E. Thinking inside and outside the envelopes of bone: dedicated to PDD. Osteoporos Int. 2009;20(8):1281-8.
51. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999;104(4):439-46.
52. Fang LC, Cheng SL, Mbalaviele G, et al. Accentuated ovariectomy induced bone loss and altered osteogenesis in hyeterozygous N-cadherin null mice. J Bone Miner Res. 2006;21(12):1897-906.
53. Bromberg O, Frisch BJ, Weber JM, Porter RL, Civitelli R, Calvi LM. Osteoblastic N-cadherin is not required for microenvironmental support and regulation of hematopoietic stem and progenitor cells. Blood. 2012;120(2):303-13.
54. Chen J, Shi Y, Regan J, Karuppaiah K, Ornitz DM, Long F. Osx-Cre targets multiple cell types besides osteoblast lineage in postnatal mice. PLoS One. 2014;9(1):e85161.